Guillermo Garcia-Manero, MD
Associate Editor
Dr. Garcia-Manero is Chief of the Section of Myelodysplastic Syndromes, Deputy Chair of Translational Research, and a Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.
Articles by Guillermo Garcia-Manero, MD
Dr. Garcia-Manero discussed luspatercept, a first-in-class drug for patients with low-risk MDS and anemia.
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, at the George R. Brown Convention Center in Houston, Texas.
Dr. Garcia-Manero discussed the phase II ASTREON trial on myelodysplastic syndromes at the 2024 ASCO Annual Meeting.
Early detection and prevention are particularly important in leukemia, Dr. Garcia-Manero explained.
The panel discusses forward-looking thoughts for the treatment of low-risk myelodysplastic syndromes.
The panel talks about the use of transplant for patients with low-risk myelodysplastic syndromes.
The panel discusses other treatments undergoing research for MDS, including imetelstat and KER-050.
The panel shared their thoughts on real-world data of luspatercept presented at ASH 2023.
The panel addresses continued MDS research needs.
The panel discusses appropriate treatment selection based on patient mutation status and comorbidities.
The panel shares their thoughts on the full analysis of the COMMANDS study.
The panel discussed the current slate of treatment options for patients with low-risk MDS.
Dr. Guillermo Garcia-Manero outlined the final data update on luspatercept in patients with MDS in the COMMANDS trial.
Guillermo Garcia-Manero, MD, discusses contemporary issues regarding the management of LR-MDS.
Dr. Garcia-Manero said he hopes to find “better treatments” and even “one day a cure for this condition.”
Guillermo Garcia-Manero, MD, joins Chadi Nabhan, MD, MBA, FACP, to discuss the COMMANDS trial at the SOHO Annual Meeting.
Guillermo Garcia-Manero, MD, the 2023 SOHO President-Elect, shares his hopes and goals for the coming years.
Dr. Garcia-Manero presented results from the phase III COMMANDS trial during the 2023 ASCO Meeting.
Dr. Garcia-Manero presented information about a phase Ib study of IRAK1/4 inhibition at the 2023 ASCO Annual Meeting.
In this video, Dr. Garcia-Manero discusses the study's primary endpoint, its implications for patients, and more.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.